Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Language
Document Type
Year range
1.
ACS Appl Bio Mater ; 5(8): 3734-3740, 2022 08 15.
Article in English | MEDLINE | ID: covidwho-1931301

ABSTRACT

The COVID-19 pandemic has demonstrated the need for versatile and robust countermeasures against viral threats. A wide range of viruses, including SARS-CoV-2, the virus that causes COVID-19, can be deactivated by metal and metal-oxide surface coatings. However, such coatings are expensive and cannot easily be retrofitted to existing infrastructure. Low-cost materials to halt the propagation of a variety of viruses must be produced with minimal quantities of expensive precursors. In this regard, we show that commercially available copper oxide nanoparticle suspensions can deactivate more than 99.55% of the human coronavirus 229E in 30 min, confirming the particles' efficiency as a fast antiviral material.


Subject(s)
COVID-19 , Pandemics , Copper/pharmacology , Humans , Oxides , Pandemics/prevention & control , SARS-CoV-2
2.
RSC advances ; 11(37):23136-23143, 2021.
Article in English | EuropePMC | ID: covidwho-1812653

ABSTRACT

To help contain the spread of the COVID-19 pandemic and to protect front-line workers, new antiviral measures are required. Antiviral nanoparticles are one such possible measure. Metal nanoparticles made from a variety of metals including gold, silver, and copper can kill or disable viruses that cause significant health problems in humans (such as SARS-CoV-2, HIV, or influenza). To promote interaction between nanoparticles and viruses the stabilizing ligands on the nanoparticle surface should be optimized for docking with proteins. The enormous chemical space of possible nanoparticle ligands makes this optimization experimentally and computationally intractable. Here we present a datamining-based study that searched for nanoparticle ligands that have previously been used, and computationally tested these for their ability to dock with the SARS-CoV-2 spike glycoprotein. These ligands will coat future antiviral nanoparticles to be used outside of the body, not as drugs. The best of these ligands identified were: nitric acid (score: 0.95), phosphoroselenoic acid (score: 0.88), hydroxyammonium (score: 0.83), pyrophosphoric acid (score: 0.81). Inspection of the best of these ligands has suggested design principles for future antiviral nanoparticle ligands, and we suggest further ligands based on these principles. These results will be used to inspire further in vitro and in silico experimentation to accelerate the development of antiviral nanoparticles. To help contain the spread of the COVID-19 pandemic and to protect front-line workers, new antiviral measures are required.

3.
RSC Adv ; 11(37): 23136-23143, 2021 Jun 25.
Article in English | MEDLINE | ID: covidwho-1327227

ABSTRACT

To help contain the spread of the COVID-19 pandemic and to protect front-line workers, new antiviral measures are required. Antiviral nanoparticles are one such possible measure. Metal nanoparticles made from a variety of metals including gold, silver, and copper can kill or disable viruses that cause significant health problems in humans (such as SARS-CoV-2, HIV, or influenza). To promote interaction between nanoparticles and viruses the stabilizing ligands on the nanoparticle surface should be optimized for docking with proteins. The enormous chemical space of possible nanoparticle ligands makes this optimization experimentally and computationally intractable. Here we present a datamining-based study that searched for nanoparticle ligands that have previously been used, and computationally tested these for their ability to dock with the SARS-CoV-2 spike glycoprotein. These ligands will coat future antiviral nanoparticles to be used outside of the body, not as drugs. The best of these ligands identified were: nitric acid (score: 0.95), phosphoroselenoic acid (score: 0.88), hydroxyammonium (score: 0.83), pyrophosphoric acid (score: 0.81). Inspection of the best of these ligands has suggested design principles for future antiviral nanoparticle ligands, and we suggest further ligands based on these principles. These results will be used to inspire further in vitro and in silico experimentation to accelerate the development of antiviral nanoparticles.

SELECTION OF CITATIONS
SEARCH DETAIL